Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label multicenter study of CT041 autologous CAR T cells in advanced gastric/gastroesophageal junction adenocarcinoma and pancreatic cancer
CTR20201940Phase 2Active
- Sponsor
- CARsgen Therapeutics
- Start
- Nov 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of satricabtagene autoleucel in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, pancreatic cancer (PC), sponsored by CARsgen Therapeutics. Started Nov 2020; status: active.
02
Drugs
satricabtagene autoleucel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomapancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20201940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201940.